CoChat

Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2

Open access
Liu, Lihong, Iketani, Sho, Guo, Yicheng, Chan, Jasper F-W., Wang, Maple, Liu, Liyuan, Luo, Yang, Chu, Hin, Huang, Yiming, Nair, Manoj S., Yu, Jian, Chik, Kenn K-H., Yuen, Terrence T-T., Yoon, Chaemin, To, Kelvin K-W., Chen, Honglin, Yin, Michael T., Sobieszczyk, Magdalena E., Huang, Yaoxing, Wang, Harris H., Sheng, Zizhang, Yuen, Kwok-Yung, Ho, David D. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)

Preprint — published as 10.1038/s41586-021-04388-0 · Paper page

PreprintCited by 142

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

The Omicron (B.1.1.529) variant of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) was only recently detected in southern Africa, but its subsequent spread has been extensive, both regionally and globally 1 . It is expected to become dominant in the coming weeks 2 , probably due to enhanced transmissibility. A striking feature of this variant is the large number of spike mutations 3 that pose a threat to the efficacy of current COVID-19 (coronavirus disease 2019) vaccines and antibody therapies 4 . This concern is amplified by the findings from our study. We found B.1.1.529 to be markedly resistant to neutralization by serum not only from convalescent patients, but also from individuals vaccinated with one of the four widely used COVID-19 vaccines. Even serum from persons vaccinated and boosted with mRNA-based vaccines exhibited substantially diminished neutralizing activity against B.1.1.529. By evaluating a panel of monoclonal antibodies to all known epitope clusters on the spike protein, we noted that the activity of 17 of the 19 antibodies tested were either abolished or impaired, including ones currently authorized or approved for use in patients. In addition, we also identified four new spike mutations (S371L, N440K, G446S, and Q493R) that confer greater antibody resistance to B.1.1.529. The Omicron variant presents a serious threat to many existing COVID-19 vaccines and therapies, compelling the development of new interventions that anticipate the evolutionary trajectory of SARS-CoV-2.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/2021.12.14.472719

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 36

  1. 10.2807/1560-7917.ES.2017.22.13.30494 · DOI · Paper page
  2. Grabowski, F. , Kochańczyk, M. & Lipniacki, T. Omicron strain spreads with the doubling time of 3.2—3.6 days in South Africa province of Gauteng that achieved herd immunity to Delta variant. medRxiv, doi:https://doi.org/10.1101/2021.12.08.21267494 (2021). · DOI
  3. 10.1126/science.abn4543 · DOI · Paper page
  4. 10.1038/s41586-021-03398-2 · DOI · Paper page
  5. 10.1056/NEJMc2104974 · DOI · Paper page
  6. 10.1056/NEJMoa2102214 · DOI · Paper page
  7. 10.1056/NEJMoa2101544 · DOI · Paper page
  8. 10.1038/s41586-021-03944-y · DOI · Paper page
  9. 10.1093/bioinformatics/bty407 · DOI · Paper page
  10. Pulliam, J. R. C. et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa. medRxiv, doi:https://doi.org/10.1101/2021.11.11.21266068 (2021). · DOI · Paper page
  11. 10.1126/science.abd0827 · DOI · Paper page
  12. 10.1038/s41586-020-2548-6 · DOI · Paper page
  13. 10.1126/scitranslmed.abf1906 · DOI · Paper page
  14. 10.1038/s41586-020-2381-y · DOI · Paper page
  15. 10.1038/s41586-020-2349-y · DOI · Paper page
  16. 10.1016/j.celrep.2021.109771 · DOI · Paper page
  17. 10.1126/science.abf4830 · DOI · Paper page
  18. 10.1016/j.cell.2021.06.021 · DOI · Paper page
  19. 10.1038/s41586-021-03817-4 · DOI · Paper page
  20. 10.1038/s41586-020-2571-7 · DOI · Paper page
  21. 10.1016/j.celrep.2021.109928 · DOI · Paper page
  22. Liu, L. et al. Isolation and comparative analysis of antibodies that broadly neutralize sarbecoviruses. bioRxiv, doi:https://doi.org/10.1101/2021.12.11.472236 (2021). · DOI
  23. 10.1056/NEJMc2114706 · DOI · Paper page
  24. 10.1038/s41586-021-03908-2 · DOI · Paper page
  25. 10.1038/s41586-021-03402-9 · DOI · Paper page
  26. Garcia-Beltran, W. F. et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. medRxiv, doi:https://doi.org/10.1101/2021.12.14.21267755 (2021). · DOI
  27. Cameroni, E. et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. bioRxiv (2021).
  28. Doria-Rose, N. A. et al. Booster of mRNA-1273 Vaccine Reduces SARS-CoV-2 Omicron Escape from Neutralizing Antibodies. medRxiv (2021).
  29. Planas, D. et al. Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization. bioRxiv (2021). · DOI
  30. 10.1016/S2666-5247(21)00267-6 · DOI · Paper page
  31. 10.1371/journal.pone.0128036 · DOI · Paper page
  32. 10.14806/ej.17.1.200 · DOI · Paper page
  33. 10.1038/nmeth.1923 · DOI · Paper page
  34. 10.1038/nbt.1754 · DOI · Paper page
  35. 10.1016/S2666-5247(20)30004-5 · DOI · Paper page
  36. 10.1016/j.jmb.2007.05.022 · DOI · Paper page

Cited by

See all 142

Metadata

Authors
Liu, L., Iketani, S., Guo, Y., Chan, J. F.-W., Wang, M., Liu, L., Luo, Y., Chu, H., Huang, Y., Nair, M. S., Yu, J., Chik, K. K.-H., Yuen, T. T.-T., Yoon, C., To, K. K.-W., Chen, H., Yin, M. T., Sobieszczyk, M. E., Huang, Y., Wang, H. H., Sheng, Z., Yuen, K.-Y., & Ho, D. D.
Venue
bioRxiv (Cold Spring Harbor Laboratory)
Publisher
openRxiv
Published
2021-12-15
OpenAlex
W4200115612
Cited by
142
References
12
Type
posted content
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2. https://app.cochat.ai/papers/10.1101/2021.12.14.472719
The paper
Liu, L., Iketani, S., Guo, Y., Chan, J. F.-W., Wang, M., Liu, L., Luo, Y., Chu, H., Huang, Y., Nair, M. S., Yu, J., Chik, K. K.-H., Yuen, T. T.-T., Yoon, C., To, K. K.-W., Chen, H., Yin, M. T., Sobieszczyk, M. E., Huang, Y., . . . Ho, D. D. (2021). Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2. bioRxiv (Cold Spring Harbor Laboratory). https://doi.org/10.1101/2021.12.14.472719

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.